• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Saluda Medical touts Evoke closed-loop SCS studies

Saluda Medical touts Evoke closed-loop SCS studies

June 3, 2019 By Fink Densford

Saluda Medical

Saluda Medical today released data from two studies of its Evoke ECAP-controlled closed-loop spinal cord stimulator.

The Evoke SCS system is designed to measure the spinal cord’s response to stimulation and adjust on every pulse to maintain activation within the patient’s therapeutic window, the Australian company said.

Results from both the Evoke and Avalon studies of the device were presented at the International Neuromodulation Society’s 14th World Congress in Sydney, Saluda Medical said.

Three-month results from the Evoke U.S. pivotal study indicated that the trial met all pre-specified endpoints and that the closed-loop system demonstrated superior back and pain relief when compared to the control in 82.3% of closed-loop subjects who achieved greater than or equal to 50% pain relief.

Data also indicated that 58.1% of closed-loop subjects were high responders with greater than or equal to 80% reduction in back and leg pain. Patients in the closed-loop group also maintained spinal cord activation within the therapeutic window at 1.5 times greater rates than the control group, Saluda said.

“Two separate studies of the Evoke System show promising results. The U.S. Evoke study, the first double-blind randomized regulatory approval study in SCS, demonstrated better rates in pain relief and secondary outcomes for closed-loop compared to control. The Avalon study, an Australian prospective, single-arm study, provides long-term evidence for sustained pain relief with closed-loop. Both studies provide evidence supporting the novel design of the device where ECAPs are measured to monitor therapy delivery in real time. The technology provides an objective measure based on a neurophysiological response to control therapy delivery and provides insight into the mechanism of action. There were a plethora of talks featuring ECAPs at this congress and they highlight the potential clinical utility of this new technology,” Evoke study investgiator Dr. Steven Falowski of Pennsylvania’s Neurosurgical Associates of Lancaster said in a press release.

Results at 18 months from the Avalon Australian study showed that 69.4% of patients experienced more than 80% pain relief, while 83.3% experienced clinically meaningful improvements in quality of life. Disability rates were also reduced, with 72.2% of patients reporting only minimal to moderate disability as compared to 18% at baseline.

Data from the Avalon study also indicated that 67.9% of patients reduced or eliminated opioid medications and that spinal cord activation was maintained within a therapeutic window 97.5% of the time.

“With Evoke, study results suggest that pain relief continues to improve over time, which is not typically observed with fixed-output systems. With the capability of neurophysiology measurements, such as percentage time in the therapeutic window, we can now start to understand a complex condition objectively in addition to patient reported outcomes, an important advancement to the field of pain management,” Avalon study investigator Dr. Charles Brooker of the Royal North Shore Hospital said in a prepared release.

In March 2017, Saluda Medical said that it raised nearly $40 million (A$53 million) for its Evoke device.

Filed Under: Clinical Trials, Featured, Pain Management, Spine Tagged With: Popular Posts, saludamedical

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy